In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Exclusivity Waiver Policy Could Change, FDA Suggests

Executive Summary

The generic drug exclusivity forfeiture provisions in the Medicare Modernization Act raise "interesting questions" about whether ANDA first-filers should be permitted to waive or relinquish their exclusivity, FDA Associate Chief Counsel Elizabeth Dickinson said

You may also be interested in...



Multiple 30-Month Stays Remain Possible Under Waxman/Hatch Reforms

Multiple 30-month stays on abbreviated new drug applications are still an option in some cases, an FDA 1draft guidance says

Generic Rx Reforms: No Automatic “Controversy” For Declaratory Judgments

The Medicare conference bill's Waxman/Hatch reform provisions would require federal courts to determine whether declaratory judgment actions brought by ANDA filers against innovators are a "case or controversy" under the Constitution

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS044971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel